GLP1 agonists have garnered significant attention lately (think injectables like Ozempic® and Trulicity®).
Small molecule researchers are also actively pursuing this target as evidenced by the consistent amount of IP publishing every month. This short video provides overall highlights and things medicinal chemists, computational chemists, and AI drug discovery researchers may want to be aware of as you generate new molecules.
Each month we use Accencio's flagship IP-GeoScape® product to highlight a biological target that currently looks to be of great interest for biopharma and AI drug discovery researchers. Although our focus will be on the intellectual property implications primarily for researchers, these highlights may also be of interest for attorneys and licensing professionals.
Accencio’s flagship product, IP-GeoScape®, is a visual landscape of the molecular IP space representing any given chemical area. The visualization tool enables researchers to See IP Differently™. Please contact us if you are interested in a demo or speaking with an IP-GeoScape expert about how we can help you.
Kevin Brogle (Ph.D.) is a co-founder and the scientific leader of Accencio® and is responsible for the creation of the Accencio landscaping technology.
Image Source: www.rcsb.org/structure/5nx2